CLINICAL, MORPHOLOGICAL, AND IMMUNOHISTOCHEMICAL PREDICTORS OF BREAST CANCER PROGNOSIS: A REVIEW OF CURRENT EVIDENCE

Authors

  • Almuradova D.M., Kurbankulov U.M. , Orifjonova I.R. Department of General Oncology, Pediatric Oncology and Palliative Care, Tashkent State Medical University, Tashkent, Republic of Uzbekistan Author

Keywords:

breast cancer, prognosis, ER, PR, HER2, Ki-67, tumor proliferation, recurrence, metastasis, personalized medicine.

Abstract

 Breast cancer remains one of the most common malignant neoplasms among women and is characterized by significant biological and clinical heterogeneity. Accurate assessment of prognostic factors is essential for predicting disease progression and selecting individualized treatment strategies. This review summarizes current evidence on the prognostic significance of clinical, morphological, and immunohistochemical characteristics of breast cancer. Particular attention is given to tumor size, lymph node involvement, histological grade, estrogen and progesterone receptors (ER and PR), HER2 status, and the Ki-67 proliferation index. The available evidence indicates that the combined assessment of these parameters provides a more comprehensive evaluation of tumor biology and individual risk of recurrence and metastasis. An integrated prognostic approach may improve risk stratification and support personalized treatment and follow-up of patients with breast cancer.

References

1.Bonacho T, Rodrigues F, Liberal J. Immunohistochemistry for diagnosis and prognosis of breast cancer: a review. Biotech Histochem. 2020;95(2):71–91. doi:10.1080/10520295.2019.1651901.

2.Penault-Llorca F, Radosevic-Robin N. Ki67 assessment in breast cancer: an update. Pathology. 2017;49(2):166–171. doi:10.1016/j.pathol.2016.11.006.

3.Nielsen TO, Leung SCY, Rimm DL, et al. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2021;113(7):808–819. doi:10.1093/jnci/djaa201.

4.Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020;38(12):1346–1366. doi:10.1200/JCO.19.02309.

5.Wolff AC, Somerfield MR, Dowsett M, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update. J Clin Oncol. 2023;41(22):3867–3872. doi:10.1200/JCO.22.02864.

6.Denkert C, Loibl S, Müller BM, et al. Ki-67 levels as predictive and prognostic parameters in breast cancer. J Natl Cancer Inst. 2013.

7.Azambuja E, Cardoso F, de Castro G Jr, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007;96:1504–1513.

8.Petrelli F, Viale G, Cabiddu M, Barni S. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Treat. 2015.

9.Assessment of Predictive Biomarkers in Breast Cancer: Challenges and Updates. 2022.

10.From Immunohistochemistry to New Digital Ecosystems: A State-of-the-Art Biomarker Review for Precision Breast Cancer Medicine. Cancers. 2022;14:3469. doi:10.3390/cancers14143469.

11.Wolff AC, Hammond MEH, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: ASCO/CAP clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013.

12.Ditsch N, Kolberg-Liedtke C, Friedrich M, et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. Breast Care (Basel). 2021;16(3):214–227. doi:10.1159/000516419.

Downloads

Published

2026-09-06